Terry D Fife1, James G Colebatch1, Kevin A Kerber1, Krister Brantberg1, Michael Strupp1, Hyung Lee1, Mark F Walker1, Eric Ashman1, Jeffrey Fletcher1, Brian Callaghan1, David S Gloss1. 1. From the Department of Neurology (T.D.F.), Barrow Neurological Institute and University of Arizona College of Medicine, Phoenix; Department of Neurology (J.G.C.), Prince of Wales Hospital, Clinical School, University of New South Wales and Neuroscience Research Australia, Randwick, Sydney; Departments of Neurology (K.A.K., B.C.) and Neurosurgery (J.F.), University of Michigan, Ann Arbor; Department of Audiology and Neurotology (K.B.), Karolinska University Hospital, Stockholm, Sweden; Department of Neurology and German Center for Dizziness and Balance Disorders (M.S.), University of Munich, Germany; Department of Neurology (H.L.), Keimyung University School of Medicine, Daegu, South Korea; Department of Neurology (M.F.W.), Case Western Reserve University, and Louis Stokes Cleveland Veterans Affairs Medical Center, OH; Bronson Neuroscience Center (E.A.), Kalamazoo, MI; and Department of Neurology (D.S.G.), Charleston Area Medical Center, WV.
Abstract
OBJECTIVE: To systematically review the evidence and make recommendations with regard to diagnostic utility of cervical and ocular vestibular evoked myogenic potentials (cVEMP and oVEMP, respectively). Four questions were asked: Does cVEMP accurately identify superior canal dehiscence syndrome (SCDS)? Does oVEMP accurately identify SCDS? For suspected vestibular symptoms, does cVEMP/oVEMP accurately identify vestibular dysfunction related to the saccule/utricle? For vestibular symptoms, does cVEMP/oVEMP accurately and substantively aid diagnosis of any specific vestibular disorder besides SCDS? METHODS: The guideline panel identified and classified relevant published studies (January 1980-December 2016) according to the 2004 American Academy of Neurology process. RESULTS AND RECOMMENDATIONS: Level C positive: Clinicians may use cVEMP stimulus threshold values to distinguish SCDS from controls (2 Class III studies) (sensitivity 86%-91%, specificity 90%-96%). Corrected cVEMP amplitude may be used to distinguish SCDS from controls (2 Class III studies) (sensitivity 100%, specificity 93%). Clinicians may use oVEMP amplitude to distinguish SCDS from normal controls (3 Class III studies) (sensitivity 77%-100%, specificity 98%-100%). oVEMP threshold may be used to aid in distinguishing SCDS from controls (3 Class III studies) (sensitivity 70%-100%, specificity 77%-100%). Level U: Evidence is insufficient to determine whether cVEMP and oVEMP can accurately identify vestibular function specifically related to the saccule/utricle, or whether cVEMP or oVEMP is useful in diagnosing vestibular neuritis or Ménière disease. Level C negative: It has not been demonstrated that cVEMP substantively aids in diagnosing benign paroxysmal positional vertigo, or that cVEMP or oVEMP aids in diagnosing/managing vestibular migraine.
OBJECTIVE: To systematically review the evidence and make recommendations with regard to diagnostic utility of cervical and ocular vestibular evoked myogenic potentials (cVEMP and oVEMP, respectively). Four questions were asked: Does cVEMP accurately identify superior canal dehiscence syndrome (SCDS)? Does oVEMP accurately identify SCDS? For suspected vestibular symptoms, does cVEMP/oVEMP accurately identify vestibular dysfunction related to the saccule/utricle? For vestibular symptoms, does cVEMP/oVEMP accurately and substantively aid diagnosis of any specific vestibular disorder besides SCDS? METHODS: The guideline panel identified and classified relevant published studies (January 1980-December 2016) according to the 2004 American Academy of Neurology process. RESULTS AND RECOMMENDATIONS: Level C positive: Clinicians may use cVEMP stimulus threshold values to distinguish SCDS from controls (2 Class III studies) (sensitivity 86%-91%, specificity 90%-96%). Corrected cVEMP amplitude may be used to distinguish SCDS from controls (2 Class III studies) (sensitivity 100%, specificity 93%). Clinicians may use oVEMP amplitude to distinguish SCDS from normal controls (3 Class III studies) (sensitivity 77%-100%, specificity 98%-100%). oVEMP threshold may be used to aid in distinguishing SCDS from controls (3 Class III studies) (sensitivity 70%-100%, specificity 77%-100%). Level U: Evidence is insufficient to determine whether cVEMP and oVEMP can accurately identify vestibular function specifically related to the saccule/utricle, or whether cVEMP or oVEMP is useful in diagnosing vestibular neuritis or Ménière disease. Level C negative: It has not been demonstrated that cVEMP substantively aids in diagnosing benign paroxysmal positional vertigo, or that cVEMP or oVEMP aids in diagnosing/managing vestibular migraine.
Authors: T D Fife; R J Tusa; J M Furman; D S Zee; E Frohman; R W Baloh; T Hain; J Goebel; J Demer; L Eviatar Journal: Neurology Date: 2000-11-28 Impact factor: 9.910
Authors: P Ashley Wackym; Jennifer A Ratigan; Jonathan D Birck; Steven H Johnson; Josef Doornink; Michael Bottlang; Stuart K Gardiner; F Owen Black Journal: Otol Neurotol Date: 2012-10 Impact factor: 2.311
Authors: S M Rosengren; S T Aw; G M Halmagyi; N P McAngus Todd; J G Colebatch Journal: J Neurol Neurosurg Psychiatry Date: 2007-08-31 Impact factor: 10.154
Authors: Anthony A Mikulec; Michael J McKenna; Mitchell J Ramsey; John J Rosowski; Barbara S Herrmann; Steven D Rauch; Hugh D Curtin; Saumil N Merchant Journal: Otol Neurotol Date: 2004-03 Impact factor: 2.311
Authors: Michael Strupp; Julia Dlugaiczyk; Birgit Bettina Ertl-Wagner; Dan Rujescu; Martin Westhofen; Marianne Dieterich Journal: Dtsch Arztebl Int Date: 2020-04-24 Impact factor: 5.594